MetaVia Reports Q1 Net Loss of $3.8M, Diluted EPS Improves to $(0.79)
MTVA sits 23% above its 52-week low of $0.966 on light trading volume (0.3× avg).
Summary
MetaVia Inc. reported a Q1 2026 net loss of $(3.8) million, largely flat year-over-year, but diluted loss per share significantly improved to $(0.79) from $(3.93) in Q1 2025. This 10-Q filing provides a crucial update on the financial health of this micro-cap biotech, especially in light of the going concern warning from its last 10-K. The company continues to invest in R&D, advancing its DA-1726 and vanoglipel programs, and has raised capital through recent offerings to fund ongoing operations. Traders will be closely monitoring future clinical trial readouts and the company's cash management as it navigates its development pipeline and seeks to monetize legacy assets.
At the time of this announcement, MTVA was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $0.97 to $19.03. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.